机译:抗肿瘤患者在复发性和转移性鼻咽癌中的抗肿瘤活性:梅奥诊所第2阶段的国际,多中心研究(NCI-9742)
Chinese Univ Hong Kong Shatin Hong Kong Peoples R China;
Natl Canc Ctr Shatin Hong Kong Peoples R China;
Natl Univ Canc Inst Singapore Singapore Singapore;
Chinese Univ Hong Kong Shatin Hong Kong Peoples R China;
Chinese Univ Hong Kong Shatin Hong Kong Peoples R China;
Mayo Clin Rochester MN USA;
Mayo Clin Rochester MN USA;
Univ Calif Davis Ctr Comprehens Canc Sacramento CA 95817 USA;
Northwestern Univ Evanston IL USA;
Johns Hopkins Univ Sch Med Baltimore MD 21218 USA;
OncoCare Canc Ctr Singapore Singapore;
Univ S Florida Moffitt Canc Ctr Tampa FL USA;
Univ S Florida Moffitt Canc Ctr Tampa FL USA;
Washington Univ Sch Med St Louis MO USA;
Univ Maryland Baltimore MD 21201 USA;
Univ Southern Calif Keck Sch Med Los Angeles CA USA;
City Hope Comprehens Canc Ctr Duarte CA USA;
Chinese Univ Hong Kong Shatin Hong Kong Peoples R China;
Chinese Univ Hong Kong Shatin Hong Kong Peoples R China;
Chinese Univ Hong Kong Shatin Hong Kong Peoples R China;
Chinese Univ Hong Kong Shatin Hong Kong Peoples R China;
Mayo Clin Rochester MN USA;
Mayo Clin Rochester MN USA;
Mayo Clin Rochester MN USA;
Chinese Univ Hong Kong Shatin Hong Kong Peoples R China;
机译:抗肿瘤患者在复发性和转移性鼻咽癌中的抗肿瘤活性:梅奥诊所第2阶段的国际,多中心研究(NCI-9742)
机译:多中心II期研究,涉及来自Mayo II期联合体患者和癌症治疗研究小组的复发或转移性鼻咽癌中AKT抑制剂MK-2206
机译:卡培他滨联合奈达铂在复发和转移性鼻咽癌顺铂化疗失败后的多中心II期研究
机译:从卷积到复发:鼻咽癌分割的案例研究
机译:云芝丹参对乳腺癌和鼻咽癌患者及类风湿关节炎灵芝三妙散的免疫调节活性的临床研究。
机译:Nivolumab在复发和转移性鼻咽癌中的抗肿瘤活性:Mayo临床2期联合会(NCI-9742)的国际多中心研究
机译:270Mo一种单臂,开放标签,复发性或转移性(R / M)鼻咽癌(NPC)患者Camrelizumab的多中心研究(NPC)≥2次化疗:船长研究